90621 Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use

Name of the Procedure:

Meningococcal Recombinant Lipoprotein Vaccine, Serogroup B (MenB-FHbp)
Commonly known as: MenB Vaccine

Summary

The MenB Vaccine is an injectable vaccine designed to protect against infections caused by Neisseria meningitidis serogroup B. It is administered in a series of 2 or 3 doses via intramuscular injection.

Purpose

The MenB Vaccine is aimed at preventing meningococcal disease caused by serogroup B bacteria. The primary goal is to reduce the risk of meningitis and bloodstream infections, which can be severe and potentially life-threatening.

Indications

• Routine vaccination for adolescents and young adults, particularly those aged 16-23.
• People in outbreak settings involving MenB disease.
• Individuals with certain medical conditions that increase risk for invasive meningococcal disease, such as asplenia or complement component deficiencies.
• Laboratory workers exposed to meningococcal bacteria.

Preparation

• No specific preparation such as fasting is required.
• Make sure the patient’s vaccination history is reviewed.
• Inform the patient of potential side effects.

Procedure Description

1. Preparation: Healthcare provider confirms the patient's identity and reviews the medical history.
2. Injection Area: The upper arm (deltoid muscle) is commonly used for the injection.
3. Administration: The vaccine is drawn up into a syringe.
4. Injection: The vaccine is administered intramuscularly in the deltoid muscle.
5. Post-Procedure: The injection site is observed for a few minutes to monitor for immediate adverse reactions.

Tools, Equipment, and Technology

• Sterile syringe and needle
• MenB-FHbp vaccine
• Alcohol swabs
• Adhesive bandage

Anesthesia or Sedation

• Not applicable; the procedure involves a simple injection that typically requires no anesthesia.

Duration

• The injection itself takes only a few minutes.
• Observation time post-injection is typically around 15 minutes to ensure no immediate allergic reactions occur.

Setting

• The procedure is typically performed in a doctor’s office, outpatient clinic, or pharmacy.

Personnel

• Licensed healthcare providers such as doctors, nurses, or pharmacists are involved.

Risks and Complications

• Common: Soreness at the injection site, mild fever, headache, fatigue.
• Rare: Allergic reactions, including anaphylaxis, though extremely uncommon.
• Management of complications involves typical monitoring for allergic reactions and providing immediate medical care if necessary.

Benefits

• Significant reduction in the risk of meningococcal serogroup B infection.
• Protection usually begins within a few weeks of completing the vaccine series.
• Contributing to herd immunity, which protects individuals who cannot be vaccinated.

Recovery

• Most individuals can resume normal activities immediately after receiving the vaccine.
• Soreness at the injection site may persist for a day or two.
• No specific follow-up is required unless adverse reactions occur, in which case a healthcare provider should be contacted.

Alternatives

• No alternative vaccines offer protection specifically against serogroup B meningococcal disease.
• Preventive measures like good hygiene and avoiding close contact during outbreaks may provide some level of prevention but are not substitutes for vaccination.

Patient Experience

• The actual injection may cause brief discomfort or a stinging sensation.
• Post-injection soreness and mild side effects are common but generally resolve quickly.
• Pain management can include over-the-counter analgesics like acetaminophen or ibuprofen if needed.

Note: Always consult with a healthcare provider for personalized medical advice.